ABANA PHARMACEUTICALS, INC. – Trademark Portfolio

Entity Type: 03

ABANA PHARMACEUTICALS, INC. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. The owner is based in BIRMINGHAM, AL.

SUITE 1111

230 OXMOOR CIRCLE

BIRMINGHAM, AL 35209

10 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

VANEX
VANEX
Abandoned 1995
ABANA
ABANA
Cancelled 1995
OTOCAIN
OTOCAIN
Cancelled 1995
OBENIX
OBENIX
Cancelled 1995
MONDE
MONDE
Abandoned 1995
TRIMMED
TRIMMED
Abandoned 1995
NASATUSS
NASATUSS
Cancelled 1993
NORCET
NORCET
Cancelled 1992
NASABID
NASABID
Cancelled 1992
VANEX-HD
VANEX-HD
Cancelled 1989

Trademark Classifications

ABANA PHARMACEUTICALS, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (9 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does ABANA PHARMACEUTICALS, INC. have?

ABANA PHARMACEUTICALS, INC. has 10 U.S. trademarks filed with the USPTO.

What trademark classes does ABANA PHARMACEUTICALS, INC. file in?

ABANA PHARMACEUTICALS, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is ABANA PHARMACEUTICALS, INC.'s trademark registration success rate?

ABANA PHARMACEUTICALS, INC. has a 0% trademark registration rate, with 0 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.